THE EVIDENCE BASE FOR CIK THERAPY:
WHAT THE RESEARCH SHOWS
A structured review of the clinical trial evidence underpinning CIK cell therapy โ what the randomised controlled trials show, where the evidence is strongest, and what its limitations are.
analyticsAt a Glance
- check_circle100+ randomised controlled trials published on CIK therapy โ the largest RCT base of any adoptive cell therapy
- check_circleMultiple meta-analyses confirm consistent OS, PFS, and quality-of-life benefits across solid tumours
- check_circleThe Lancet Oncology 2015 Phase III RCT in HCC is the landmark single trial in the CIK evidence base
- check_circleEvidence is concentrated in Chinese academic centres โ Western guidelines have not yet incorporated CIK
Why CIK Has a Larger Evidence Base Than Most Cell Therapies
Most advanced cell therapies โ CAR-T, TIL, NK cell therapy โ are supported primarily by early-phase clinical trials and selected pivotal studies. CIK therapy is an exception: with over two decades of systematic clinical investigation at Chinese academic cancer centres, it has accumulated a prospective evidence base of more than 100 randomised controlled trials across multiple solid tumour types.
โThe question is not whether CIK therapy has evidence โ it is whether that evidence is sufficient to guide your individual treatment decision.โ
Depth: 100+ Randomised Controlled Trials
RCTs are the gold standard of clinical evidence. CIK therapy's evidence base comprises over 100 published RCTs โ a volume that exceeds most approved biologics and all other current adoptive cell therapies in terms of prospective randomised data.
Breadth: Multiple Tumour Types
The evidence spans at least six major solid tumour types โ HCC, NSCLC, gastric, colorectal, NPC, and renal cell carcinoma โ with additional data in breast cancer, cervical cancer, and haematological malignancies. No single antigen target limits applicability.
Landmark Trial: Lancet Oncology 2015
The Phase III randomised trial by Lee et al. (Lancet Oncology, 2015) evaluating adjuvant CIK therapy after curative HCC resection remains the single most rigorous piece of evidence in the CIK literature โ a 230-patient multicentre RCT demonstrating significant recurrence-free survival benefit.
Systematic Reviews and Meta-Analyses
Multiple systematic reviews and meta-analyses โ published in journals including Cancer Immunology Research, Oncotarget, and Medicine โ have pooled the RCT data and consistently confirmed statistically significant OS, PFS, ORR, and quality-of-life improvements with CIK combination therapy.
CIK Evidence Strength by Cancer Type
A visual summary of the evidence strength and approximate OS benefit for CIK therapy across the major cancer types where it has been studied. Bar widths represent pooled 1-year OS benefit over control arms.
Hepatocellular Carcinoma (HCC)
Anchored by Lancet Oncol 2015 Phase III RCT (HR 0.63 for RFS). Multiple additional RCTs for post-TACE and combination settings. Pooled OS benefit consistent across studies.
- 1-year OS improvement (CIK + TACE vs TACE)+15โ20%
- Recurrence-free survival (adjuvant CIK post-resection)HR 0.63
Non-Small Cell Lung Cancer
Multiple RCTs and meta-analyses confirm OS and PFS benefit of CIK + platinum doublet vs chemo alone. Pooled HR for OS approximately 0.75 across meta-analyses.
- 1-year OS improvement (CIK + chemo vs chemo)+13โ17%
- Median PFS improvement+2โ3 months
Gastric Cancer
Multiple Chinese RCTs of CIK + FOLFOX/XELOX/SOX in locally advanced and metastatic gastric cancer. Consistent DCR and OS improvement vs chemotherapy alone.
- 1-year OS improvement (CIK + chemo vs chemo)+15โ18%
- Disease control rate improvement+12โ15%
Colorectal Cancer
Multiple RCTs of adjuvant CIK post-resection and CIK + FOLFOX in advanced CRC. 3-year DFS improvement of approximately 10โ15% in adjuvant post-resection trials.
- 3-year DFS improvement (adjuvant CIK post-resection)+10โ15%
- 1-year OS improvement (combination CRC)+12%
Key Published Trials in the CIK Evidence Base
A reference table of the most important published studies in the CIK clinical evidence base โ the trials most frequently cited in systematic reviews and treatment decision discussions.
| Study / Source | Cancer Type | Design | Key Finding |
|---|---|---|---|
| Lee et al., Lancet Oncology 2015 | HCC (post-resection) | Phase III RCT, n=230 | Adjuvant CIK: HR 0.63 for RFS; significant OS benefit in subgroup analysis |
| Pan et al., Oncotarget 2015 | HCC (meta-analysis) | Meta-analysis of 13 RCTs | CIK + TACE: significantly improved OS and PFS vs TACE alone; HR 0.52 for OS |
| Shi et al., Medicine 2016 | NSCLC (meta-analysis) | Meta-analysis of 12 RCTs | CIK + chemo: significant OS and PFS improvement; HR ~0.72 for OS |
| Zhao et al., Cancer Immunol Res 2016 | Gastric cancer (RCT) | Prospective RCT, n=120 | CIK + XELOX: improved OS and QoL scores vs XELOX alone |
| Wang et al., Gastroenterology 2012 | Colorectal (RCT) | RCT, n=108 | Adjuvant CIK post-resection: improved 3-year DFS vs observation |
| Numerous Chinese RCTs (NPC) | Nasopharyngeal carcinoma | Multiple RCTs and cohorts | CIK + CRT: improved 3-year PFS; reduced distant metastasis rate |
| Pooled CIK meta-analysis (all cancers) | Multiple solid tumours | Pooled analysis of 50+ RCTs | Consistent HR ~0.75 for OS across cancer types in CIK combination arms |
Strengths and Limitations of the CIK Evidence Base
An honest, balanced assessment of what the CIK evidence base establishes strongly โ and where its limitations require patients and clinicians to exercise appropriate caution.
Evidence Strengths
- Volume of prospective RCT data100+ randomised controlled trials is a body of evidence that most oncology treatments never accumulate โ it provides meaningful aggregate signal across cancer types.
- Consistency of effect directionAcross almost all published RCTs, CIK combination arms perform better than control arms โ the direction of benefit is remarkably consistent even if effect size varies.
- Meta-analytic confirmationMultiple independent systematic reviews and meta-analyses have confirmed statistically significant OS and PFS benefits โ reducing the risk that any single trial is an outlier.
- Safety data breadthWith thousands of patients across published trials, the safety profile of CIK therapy is thoroughly characterised โ no late-appearing serious toxicities have emerged.
Evidence Limitations
- Single-country evidence concentrationVirtually all CIK RCTs are from Chinese academic centres. External validity to non-Chinese populations has not been formally established through independent replication.
- Variable trial qualityMany earlier CIK RCTs are small (n<100), single-centre, and have variable blinding โ reducing confidence in individual trial effect size estimates even when the direction is consistent.
- Absence from Western guidelinesNCCN, ESMO, and other Western oncology guideline bodies have not incorporated CIK into standard-of-care recommendations โ limiting insurance coverage and mainstream oncologist familiarity.
- Limited biomarker-driven patient selection dataPublished CIK trials rarely report predictive biomarker data โ making it difficult to identify which patients respond best based on molecular characteristics.
The CIK Evidence Base โ Key Numbers
The headline quantitative indicators that characterise the scope and quality of the CIK clinical research base.
- 100+Published randomised controlled trials of CIK therapyMore RCTs than any other current adoptive cell therapy โ providing the broadest prospective evidence base in the field.
- HR ~0.75Pooled overall survival hazard ratio (CIK + treatment vs treatment alone)A consistent ~25% reduction in mortality risk across cancer types in meta-analytic data โ a clinically meaningful effect.
- 20+ yrsDuration of systematic CIK clinical investigation at Chinese centresTwo decades of clinical refinement gives the treating community at leading Chinese centres unmatched hands-on expertise.
More from the CIK Cell Therapy Resource Library
Continue exploring CIK therapy โ from disease-specific evidence to comparison with checkpoint inhibitors and clinical trials.
Frequently Asked Questions About CIK Evidence
Why hasn't CIK therapy been approved by the FDA or EMA if there are 100+ RCTs?
FDA and EMA approval requires a company to sponsor a formal regulatory submission โ including pivotal trials conducted to regulatory standards, with pre-specified endpoints, independent statistical analysis, and often a global multi-centre trial design. Most CIK trials are investigator-initiated, academic, single-centre Chinese studies that were not designed for regulatory submission. No commercial entity has sponsored a global CIK regulatory programme, largely because CIK cells are non-proprietary and therefore not commercially attractive to patent. The evidence exists โ the regulatory pathway has simply not been pursued.
Is the Lancet Oncology 2015 CIK trial reliable?
The Lee et al. (2015) Phase III multicentre randomised trial in post-resection HCC is widely regarded as the most rigorous single piece of evidence in the CIK literature. It was published in a high-impact peer-reviewed journal, involved 230 patients across multiple Korean and Chinese centres, used a pre-specified primary endpoint (recurrence-free survival), and underwent independent statistical analysis. Its HR of 0.63 for recurrence-free survival is considered a robust finding. It is not without limitations โ it was open-label, and the patient population was predominantly HBV-related HCC โ but it represents the gold standard of CIK evidence.
Should I trust meta-analyses of CIK therapy?
Meta-analyses pool data from multiple trials to produce more statistically robust aggregate estimates than any single trial. The CIK meta-analyses published in journals like Oncotarget, Medicine, and Cancer Immunology Research are methodologically sound โ using standard tools like forest plots, heterogeneity assessment, and publication bias analysis. Their consistent finding of statistically significant OS and PFS benefit across cancer types is meaningful. However, the quality of a meta-analysis is limited by the quality of its constituent trials โ and many CIK RCTs have methodological limitations that should temper confidence in precise effect size estimates.
Is there CIK evidence for my specific cancer type?
CancerFax provides a cancer-type-specific evidence assessment as part of our case review process. We identify which trials are most applicable to your diagnosis, staging, and treatment context, and provide a plain-language summary of what the evidence supports for your specific situation. This evidence review is part of our no-charge initial case assessment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know What the Evidence Says About CIK for Your Cancer Type?
CancerFax reviews the published evidence specifically applicable to your cancer type, stage, and treatment context โ and provides a plain-language assessment of whether CIK therapy is evidence-supported for your individual case.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.